SEC Filings

8-K
PERNIX THERAPEUTICS HOLDINGS, INC. filed this Form 8-K on 02/19/2019
Entire Document
 

 

8 ▪ Pernix provides a strong platform with a turnaround - focused management team and a scalable sales force ▪ Pernix Prescriptions Direct (“PPD”) helps patients overcome some of the challenges that they might confront when obtaining their medication ▪ For Treximet ® and Silenor ® , ~33K patients enrolled have received ~200K TRx since inception. For Zohydro ® ER, over 26K TRx shipped through 3 partner pharmacies since mid - 2017 national launch ▪ Fully integrated and dedicated specialty sales force with expertise in promoting brands in pain and CNS, supplemented by best - in - class prescription fulfillment service ▪ Ability to leverage platform, including PPD, through additional assets in pain and pain - adjacent therapeutic areas, as well as to capitalize on other assets opportunistically (e.g. Contrave ® ) ▪ Track record of driving operational efficiencies and cost savings through expertise in strategy, operations and financial advisory ▪ Proven track record of driving growth in target markets with an ability to pivot across therapeutic specialties. Adept at leveraging pharmacy access programs to drive enhanced growth Proven Leadership Team with Success in Driving Cost Savings Poised to Capitalize on Business Development Opportunities Impactful Sales Force and Scalable Platform Attractive Commercial Platform with Leading Pain Franchise 1 4 5 2 Scalable Prescription Fulfillment Service 3 Pernix Strategic Highlights